Mdm2 promotes the rapid degradation of p53 - Nature
- ️Oren, Moshe
- ️Thu May 15 1997
References
Gottlieb, T. & Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287, 77–102 (1996).
Shen, Y. & Shenk, T. E. Viruses and apoptosis. Curr. Opin. Gene. Dev. 5, 105–111 (1995).
Picksley, S. M. & Lane, D. P. The p53–mdm2 autoregulatory feedback loop—a paradigm for the regulation of growth control by p53? Bioessays 15, 689–690 (1993).
Chen, J. D., Lin, J. Y. & Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1, 141–142 (1995).
Chen, C. Y. et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sc. USA 91, 2684–2688 (1994).
Haupt, Y., Barak, Y. & Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15, 1596–1606 (1996).
Chen, J. D., Wu, X., Lin, J. Y. & Levine, A. J. mdm-2 inhibitis the Gl arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16, 2445–2452 (1996).
Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. & Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA 90, 11623–11627(1993).
Barak, Y., Gottlieb, E., Juven-Gershon, T. & Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739–1749 (1994).
Lin, J. Y., Chen, J. D., Elenbaas, B. & Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235–1246 (1994).
Hinds, P. W. et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells-a comparison of the hot spot mutant phenotype. Cell Growth Diff. 1, 571–580 (1990).
Unger, T., Nau, M. M., Segal, S. & Minna, J. D. p53—a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11, 1383–1390 (1992).
Oren, M., Reich, N. C. & Levine, A. J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol. 2, 443–449 (1982).
Yonish-Rouach, E. et al. Induction of apoptosis by transiently transfected metabolically stable wt p53 is transformed cell lines. Cell Death Differ. 1, 39–47 (1994).
Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κBl precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
Maki, C. J., Huibregtse, J. M. & Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649–2654 (1996).
Kubbutat, M. H. & Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17, 460–468 (1997).
Gottlieb, E., Lindner, S. & Oren, M. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth Diff. 7, 301–310 (1996).
Lane, D. P. The regulation of p53 function: Steiner award lecture. Int. J. Cancer 57, 623–627 (1994).
Bartek, J., Iggo, R., Gannon, J. & Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893–899 (1990).
Martin, K. et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 575, 691–694 (1995).
Xiao, Z. X. et al. Interaction between the retinoblastoma protein and the oncoprotein Mdm2. Nature 375,694–698 (1995).
Momand, J. & Zambetti, G. P. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12, 2279–2289 (1996).
Kastan, M. B., Onyekwere, O., Sindransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304–6311 (1991).
Fiscella, M. et al. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8, 1519–1528 (1993).
Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495–505 (1993).
Otto, A. & Deppert, W. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene 8, 2591–2603 (1993).
Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 378, 206–208 (1995).
Monies de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).